Response Assessment in Neuro-Oncology Criteria: Implementation Challenges in Multicenter Neuro-Oncology Trials

References

1. 1.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA,
   4. et al

   . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963–72

   Abstract/FREE Full Text
2. 2.↵
   1. Macdonald DR,
   2. Cascino TL,
   3. Schold SC,
   4. et al

   . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–80

   Abstract
3. 3.↵
   1. Norden AD,
   2. Young GS,
   3. Setayesh K,
   4. et al

   . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779–87

   Abstract/FREE Full Text
4. 4.↵
   1. Roth P,
   2. Wick W,
   3. Weller M

   . Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 2010; 23: 597–602

   CrossRefPubMed